ISRCTN39055704
Completed
Not Applicable
Phase III project, randomised controlled trial of brief intervention for illicit drugs linked to the World Health Organization (WHO) alcohol, smoking and substance involvement screening test (ASSIST): multicentre study conducted in Australia, Brazil, India, Spain, Thailand and USA
World Health Organization (WHO)/The Department of Mental Health and Substance Abuse (MSD) (Switzerland)0 sites1,047 target enrollmentFebruary 8, 2005
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Substance abuse
- Sponsor
- World Health Organization (WHO)/The Department of Mental Health and Substance Abuse (MSD) (Switzerland)
- Enrollment
- 1047
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age 18 \- 50 years
- •2\. Member of main ethnic group in the population
- •3\. Able to communicate in the national language
- •4\. Willing for three month follow\-up
- •5\. Be able to be followed up three months later and give contact details of two to three other people
- •6\. Have a fixed address and provide contact details of their home
Exclusion Criteria
- •1\. Any pending court session with possible incarceration within three months
- •2\. Any severe intellectual disability or cognitive impairment
- •3\. Severe behaviour disturbance or psychotic symptoms
- •4\. Tendencies to violent or aggressive behaviour
- •5\. Intoxicated or withdrawal from alcohol or drugs
- •6\. Incarcerated or in the environment with no free movements in the last three months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Phase III randomised, controlled trial of exercise during chemotherapy for patients commencing first line treatment for ovarian cancerOvarian CancerCancer - Ovarian and primary peritonealACTRN12614001311640niversity of Sydney524
Completed
Not Applicable
A phase III open, randomised, controlled study to evaluate the safety and immunogenicity of a paediatric dose (0.25 ml) and the standard dose (0.5 ml) of Epaxal® with reference to comparator vaccine in healthy children and adolescents (12 months to 16 years of age inclusive), using a 0/6 month scheduleHepatitis A VirusInfections and InfestationsHepatitisISRCTN91009479Berna Biotech AG (Switzerland)360
Active, not recruiting
Not Applicable
A phase III randomised, controlled study to assess in a double blind manner the lot-to-lot consistency of three consecutive production lots of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine and to evaluate the non-inferiority to Prevenar™ in a single blind design, when administered as a 3-dose primary immunization course before 6 months of age. - 10PN-PD-DIT-001EUCTR2005-003300-11-FIGlaxoSmithKline Biologicals1,600
Active, not recruiting
Not Applicable
A phase IIIa open, randomised, controlled study to assess the safety, reactogenicity and immunogenicity induced by a booster dose of GlaxoSmithKline (GSK) Biologicals 10-valent pneumococcal conjugate vaccine when co-administered with GSK Biologicals’ measles-mumps-rubella-varicella vaccine (MMRV) vaccine in children during their second year of life, previously vaccinated in infancy in the primary study 10PN-PD-DIT-001 (105553) with GSK Biologicals 10-valent pneumococcal conjugate vaccine. - 10PN-PD-DIT-022 BST: 001Booster vaccination against Streptococcus pneumoniae and active immunization against measles, mumps, rubella and varicella diseases in children during the second year of life.EUCTR2006-001934-42-FIGlaxoSmithKline Biologicals400
Recruiting
Phase 3
Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 Gastric Cancer patients (JCOG1907, MONA LISA study)clinical stage T1-4aN0-3 Gastric CancerJPRN-UMIN000039825Japan Clinical Oncology Group (JCOG)1,040